Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY [NYSE]
Sanofi
Index- P/E26.96 EPS (ttm)1.86 Insider Own- Shs Outstand2.62B Perf Week-2.73%
Market Cap131.60B Forward P/E16.13 EPS next Y3.11 Insider Trans- Shs Float2.39B Perf Month-1.99%
Income4.92B PEG4.61 EPS next Q- Inst Own9.60% Short Float0.07% Perf Quarter6.86%
Sales38.20B P/S3.44 EPS this Y18.70% Inst Trans-0.44% Short Ratio1.11 Perf Half Y8.46%
Book/sh23.08 P/B2.17 EPS next Y2.98% ROA4.60% Target Price55.67 Perf Year-4.70%
Cash/sh3.12 P/C16.08 EPS next 5Y5.85% ROE7.90% 52W Range43.57 - 57.42 Perf YTD9.95%
Dividend1.62 P/FCF- EPS past 5Y-4.00% ROI7.00% 52W High-13.88% Beta0.98
Dividend %3.23% Quick Ratio1.30 Sales past 5Y1.80% Gross Margin67.70% 52W Low13.50% ATR0.84
Employees113496 Current Ratio1.80 Sales Q/Q7.30% Oper. Margin19.20% RSI (14)40.43 Volatility1.56% 1.22%
OptionableYes Debt/Eq0.26 EPS Q/Q31.70% Profit Margin12.40% Rel Volume0.89 Prev Close50.15
ShortableYes LT Debt/Eq0.24 EarningsApr 30 BMO Payout49.10% Avg Volume1.54M Price49.45
Recom1.70 SMA20-4.18% SMA50-1.46% SMA200-1.28% Volume1,376,631 Change-1.40%
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Jul-18-07Upgrade HSBC Securities Neutral → Overweight
Jun-14-07Reiterated Banc of America Sec Buy $50 → $48
May-06-15 03:39PM  Today's Top 5 Stock Picks: Undervalued Global Giants at Barrons.com
06:00AM  Hot Drugs Show Sharp Price Hikes in Shadow Market
06:00AM  Diabetes Drugs Compete With Prices That Rise in Lockstep at Bloomberg
May-05-15 09:00AM  Majority of Canadians unprepared for an allergy emergency. Team Allerject educates to save lives PR Newswire
09:00AM  Majority of Canadians unprepared for an allergy emergency. Team Allerject educates to save lives CNW Group
07:36AM  L'Oreal S.A. -- Moody's affirms L'Oreal S.A.'s Prime-1 rating at Moody's
May-04-15 01:07PM  Sanofi: Annual General Shareholder Meeting of May 4, 2015 at noodls
12:31PM  Sanofi rebels make mark in AGM vote on CEO pay
May-01-15 10:55AM  Sanofi Misses on Q1 Earnings by a Penny, Maintains Outlook - Analyst Blog
09:02AM  Will Sanofi's Big Bet On Vaccines Pull It Out Of Its Diabetes Slump? at Forbes
Apr-30-15 05:17PM  Early sales of MannKind inhaled insulin drug disappoint Wall Street at Los Angeles Times
03:22PM  Sanofi faces AGM row over cost of firing and hiring CEOs Reuters
02:56PM  Biotech boom land grab
11:50AM  Pharma: No standout performers
08:50AM  Potential Peninsula biotech IPO lands $46 million at bizjournals.com
07:53AM  Sanofi Delivers Q1 2015 Business EPS Growth of 2.6% at CER and 12.8% on a Reported Basis PR Newswire
07:35AM  Sanofi Says Diabetes Revenue to Fall at The Wall Street Journal
07:08AM  European drugmakers lifted by weak euro at Financial Times
06:51AM  MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales at TheStreet
06:29AM  UPDATE 2-Sanofi warns of lower diabetes drug sales this year
04:35AM  Drugmaker Sanofi sees Q1 profit drop amid leadership change
01:52AM  Sanofi Q1 2015 Results - Interview With CFO Jérôme Contamine PR Newswire
01:42AM  Sanofi keeps 2015 guidance with steady Q1 profits
01:30AM  Sanofi Diabetes Sales Drop After Lantus Gets Price Cut in U.S. at Bloomberg
12:43AM  Sanofi delivers Q1 2015 Business EPS(1) growth of 2.6% at CER(2) and 12.8% on a reported basis ACN Newswire
Apr-29-15 06:18PM  Sanofi's (SNY) Basal Insulin Toujeo Gains European Approval - Analyst Blog
03:34PM  Januvia Passes, Afrezza On Deck at Forbes
01:18PM  Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings at TheStreet
Apr-28-15 04:10PM  Partners looks to commercialize innovation with international forum at bizjournals.com
09:38AM  Sanofi: Toujeo® Approved in the European Union for the Treatment of Diabetes in Adults at noodls
01:22AM  Sanofi says U.S. FDA to fast track Fabry therapy review Reuters
01:17AM  Sanofi: FDA Grants Fast Track Designation to Genzyme's Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease at noodls
01:00AM  FDA Grants Fast Track Designation to Genzymes Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease Business Wire
Apr-27-15 05:11PM  More Preliminary Signs That The New Cholesterol Drugs May Improve Outcomes at Forbes
03:02PM  ImmunoGen skids after disclosing drug development setbacks
10:17AM  Synta Pharmaceuticals names third CEO since March 2014 at bizjournals.com
Apr-23-15 09:04AM  Sanofi: Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years at noodls
09:00AM  Effect of Genzymes Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years Business Wire
Apr-22-15 02:02PM  Alnylam Reports Positive Patisiran Results, Shares Up - Analyst Blog
01:50PM  How a Stronger US Dollar Has Affected Large-Cap Stocks
11:43AM  Amgen: But What About the Biosimilars? at Barrons.com
06:39AM  Sanofi-Aventis upgraded by Citigroup
Apr-21-15 09:00AM  Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease Business Wire
Apr-17-15 10:44AM  Bristol's Opdivo Scores Again Against Lung Cancer at Investor's Business Daily
Apr-16-15 12:00PM  Actelion to Boost Progress of Specialty Immunology Pipeline - Analyst Blog
Apr-14-15 07:06PM  The Medicines Co.'s Kengreal Briefing Documents Positive - Analyst Blog
Apr-13-15 05:00PM  Fewer CEOs Fired and More Retired Save Shareholders Billions at Bloomberg
05:00PM  Fewer CEOs Are Being Fired and That's Good News for Shareholders
02:10PM  Wave of interest in gene therapy brings Voyager a new $60M investment at bizjournals.com
09:00AM  Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) at AAN Business Wire
Apr-10-15 08:30AM  Trade Europe and a Strong USD with this ETF at Investopedia
Apr-09-15 10:51AM  Inverse Head and Shoulders Patterns Breaking Out at Investopedia
Apr-08-15 02:03PM  What Really Happens To Stocks When The Fed Tightens Monetary Policy? at Forbes
Apr-07-15 01:30PM  Sanofi: Shantha will provide up to 37 million doses of Shan5(TM) at noodls
01:30PM  Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide) at noodls
01:30PM  Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine at noodls
12:19AM  [$$] Bristol-Myers Invests in Dutch Company uniQure at The Wall Street Journal
Apr-06-15 05:27PM  Bristol-Myers Invests in uniQure in Heart-Disease Pact at The Wall Street Journal
12:15PM  Alnylam to move HQ to former Vertex site in big 2018 biotech shuffle at bizjournals.com
Apr-03-15 07:25AM  GlaxoSmithKline to move 150 Cambridge vaccine research jobs out of state at bizjournals.com
06:10AM  Foreign-owned companies find Mass. appeal-ing at bizjournals.com
Apr-02-15 02:23PM  Boston Business Journal announces 2015 Women to Watch in Science and Technology honorees at bizjournals.com
01:55PM  BioMed scores against rival Alexandria with new lease to Biogen at bizjournals.com
Apr-01-15 06:36PM  Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog
03:44PM  Esperion Up As UBS Touts Cholesterol Drug at Investor's Business Daily
12:31PM  What are examples of major companies in the drugs sector? at Investopedia
Mar-31-15 02:45PM  On the move: New hires and job transitions in the local life science industry at bizjournals.com
12:06PM  Pfizers Global Innovative Pharmaceutical Segment
Mar-30-15 06:06PM  What Products Affect Pfizers Revenue?
02:29PM  Nigerian Elections Extended Amid Glitches, Disruptions at MarketWatch
11:00AM  Genzymes Cerdelga® (eliglustat) Capsules Approved in Japan Business Wire
Mar-27-15 12:37PM  11 promising drugs poised to be the next billion-dollar blockbusters
12:00PM  Source to Close Europe ETF
Mar-26-15 06:40PM  Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog
01:30PM  Genzyme Convenes Sixth Annual Gaucher Leadership Forum Business Wire
Mar-25-15 09:12PM  ENCORE Clinical Data Published in The Lancet Suggest Treatment with Oral Maintenance Therapy Effective in Previously Treated Gaucher Disease Patients Business Wire
12:15PM  Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years of Age PR Newswire
Mar-24-15 04:51PM  Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog
Mar-23-15 02:58PM  11 Promising New Drugs Expected to Make Billions in Sales at TheStreet
Mar-20-15 05:25PM  Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog
04:38PM  Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog
09:00AM  Goldman Downgrade Makes MannKind A Buy at Forbes
Mar-19-15 08:11PM  Evotec and Sanofi Sign Definitive Agreement for Major Multi-Component Strategic Alliance GlobeNewswire
03:01PM  Mark Levin to be honored with MassBio's annual Termeer award at bizjournals.com
11:03AM  Amicus Up As FDA, EU Green-light Quick Drug Filings at Investor's Business Daily
10:38AM  Novo Nordisk On Diversity In Diabetes Trials: "We Could Do Better" at Forbes
09:03AM  5 Breakout Stocks to Trade for Gains After the Fed's Bombshell at TheStreet
07:00AM  Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide) PR Newswire
02:11AM  Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(r) (lixisenatide) GlobeNewswire
Mar-18-15 03:45PM  Investors Relieved? Akorn Stock Retakes 50-Day Line at Investor's Business Daily
01:00PM  To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher at bizjournals.com
11:00AM  The Temptation of International Dividend ETFs ETF Trends
10:50AM  Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog
09:17AM  MannKind's Financial Health Complicated by Looming $100M Debt Payment at TheStreet
08:45AM  Nasacort® Allergy 24HR Partners with The Book of Awesome Author and Renowned Smell Expert to Celebrate the Happy Smells of Spring PR Newswire
Mar-17-15 11:39AM  Sanofi Upgraded On FX, Cholesterol Drug Promise at Investor's Business Daily
03:00AM  Form 20F for Sanofi at Company Spotlight
Mar-16-15 08:28PM  Top Stock Regeneron Breaks Out On Big Drug News at Investor's Business Daily
05:59PM  Regeneron/Sanofi's PCSK9 Drug Praluent Data Published - Analyst Blog
05:03PM  Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerDec 24Buy398.7930,00211,964,50122,859,144Dec 29 05:40 PM
Sanofi10% OwnerDec 23Buy392.23171,45767,251,14222,829,142Dec 29 05:40 PM
Sanofi10% OwnerOct 16Buy335.35122,12740,955,05722,657,685Oct 20 05:45 PM
Sanofi10% OwnerOct 15Buy328.16158,36851,970,26522,535,558Oct 17 05:05 PM
Sanofi10% OwnerJul 15Buy314.92129,10040,656,17622,204,841Jul 17 05:50 PM
Sanofi10% OwnerJul 14Buy318.18150,00047,726,79722,075,741Jul 15 05:45 PM
Sanofi10% OwnerJul 11Buy315.41150,00047,311,83621,925,741Jul 15 05:45 PM
Sanofi10% OwnerJul 10Buy311.08175,00054,439,07321,775,741Jul 14 05:46 PM
Sanofi10% OwnerJul 09Buy308.27195,00060,112,31121,600,741Jul 10 05:45 PM
Sanofi10% OwnerJul 08Buy311.67153,00047,685,74321,405,741Jul 10 05:45 PM
Sanofi10% OwnerJul 07Buy312.90256,70080,320,79521,252,741Jul 08 05:42 PM
Sanofi10% OwnerJul 03Buy311.02100,00031,101,94620,996,041Jul 08 05:42 PM
Sanofi10% OwnerJul 02Buy307.25212,40065,259,55220,896,041Jul 03 06:00 PM
Sanofi10% OwnerJul 01Buy300.20212,40063,761,42120,683,641Jul 03 05:46 PM
Sanofi10% OwnerJun 30Buy282.54212,40060,010,47920,471,241Jul 01 05:39 PM
Sanofi10% OwnerJun 27Buy275.3850,00013,769,09220,258,841Jul 01 05:39 PM
Sanofi10% OwnerMay 19Buy300.04190,75157,233,71620,208,841May 21 05:02 PM